朗生醫藥(00503.HK)出售合共96.3萬股司太立股份
格隆匯4月15日丨朗生醫藥(00503.HK)公佈,於2021年3月24日至2021年4月15日期間,根據司太立出售授權及第七次股份減持計劃,公司以平均每股人民幣61.53元的價格在市場出售合共96.3萬股司太立股份,出售所得款項總額約為人民幣5924萬元。集團預計本次出售將確認按公平值計入損益的金融資產的變現虧損(扣除交易成本及相關税款)約115萬美元,該變現虧損是根據出售淨收益與該出售部份的按公平值計入損益的金融資產於2020年12月31日時的賬面值計算。
公司自獲得司太立出售授權之日起合共出售了711.7萬股司太立股份。在本次出售後,集團仍持有228.5萬股司太立股份,其價值會受市場價格波動所影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.